Studies of inherited mutations underlying rare human disorders elucidate genes and pathways of fundamental importance to human health. The phosphoinositide 3-kinase (PI3K) pathway has recently been ...

They find no evidence of hyperactive PI3K signalling monitored by pAKT in APDS2 patient-derived dermal fibroblast cells. In these cells p110 alpha protein levels were comparable to levels in control ...

PTEN loss, one of the most frequent mutations in prostate cancer (PC), is presumed to drive disease progression through AKT activation. However, two transgenic PC models with Akt activation plus Rb ...

The PI3K family is divided into three classes (classes 1–3) according to structural differences. Class 1 is the most widely studied and is further subcategorized into 1A and 1B subtypes, which ...

Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme. The PI3K-delta ...

Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal ...

We have 2 PI3-kinase inhibitors that are approved right now. There are others that are in development. They all have some subtle differences. Of the 2 that are approved, idelalisib is oral. Copanlisib ...

Therapeutic benefit of selective inhibition of p110 PI3-kinase in pancreatic neuroendocrine tumors. Clinical Cancer Research, 2016; DOI: 10.1158/1078-0432.CCR-15-3051 ...

To test the specificity of PI3K inhibitors in cellular system, we generated a panel of human rhabdomyosarcoma Rh30 cell lines that stably expressed one myristoylation (Myr)-tagged p110 catalytic ...

Under the terms of the agreement, the team will further interrogate the mechanism by which Karus Therapeutics’ PI3K-p110 beta and PI3K-p110 delta inhibitors impact on neutrophil function and immune ...